Dec 09, 2021
AIM ImmunoTech's Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza
Dec 06, 2021
AIM ImmunoTech CEO to Participate in Two Upcoming Investor Conferences
Nov 16, 2021
AIM ImmunoTech Provides Third Quarter 2021 Business Update
Oct 19, 2021
AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer
Oct 06, 2021
AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy
Oct 04, 2021
AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer
Sep 30, 2021
AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses
Sep 28, 2021
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19
Sep 27, 2021
AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses
Sep 21, 2021
AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction
 7   8   9   10   11     12    13   14   15   16   17 
 <<   <   >   >>